news-medical.net
Cure8 news brief
Why This Matters
This study tests whether a ‘microbiome reboot’ — using exclusive enteral nutrition followed by fecal microbiome transfer — can make the beneficial microbiome changes last longer and help keep Crohn’s disease in remission.
Who Should Pay Attention
People with Crohn’s disease (including pediatric patients), caregivers, gastroenterologists, and researchers interested in microbiome-based therapies and dietary interventions.
Study Snapshot
Story typeResearch news
Evidence typePhase 1 clinical trial
Source depthFull source text
What To Know
Researchers at TUM and LMU studied how exclusive enteral nutrition (EEN) changes the gut microbiome and are launching a clinical study combining EEN with fecal microbiome transfer (FMT) capsules from screened healthy donors to try to prolong remission in Crohn’s disease.
In lab models, microbiomes pre-adapted with the EEN formula prevented inflammation in mice; non-adapted microbiomes did not. The human study will assess safety, feasibility, and whether FMT after EEN can stabilize or delay recurrence of inflammation.
Keep In Mind
Findings are based on laboratory and animal-model work and motivate a clinical study now underway. The article reports the planned human trial will test safety and feasibility; it does not present clinical outcomes in people yet.
Fecal microbiome transfer is an active research area with varying results across conditions; follow-up and peer-reviewed trial results will be needed before changing care.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationnews-medical.net
Indexed viaGoogle News
Source typeResearch news
PublishedFeb 11, 2025, 5:11 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Microbiome shift linked to Crohn's disease remission sparks clinical study on new therapy
This reports a potential new way to extend remission after exclusive enteral nutrition by combining diet with fecal microbiome transfer—an approach that targets the gut microbiome rather than adding drugs. If effective,...
Faecalibacterium prausnitzii Trial for Crohn's Disease Remission - Bioengineer.org
This study tests a live Faecalibacterium prausnitzii probiotic (EXL01) as a way to prolong steroid-induced remission in Crohn’s disease, a potential new strategy to reduce relapses and steroid exposure.
Microbiome Breakthrough: New Crohn's Treatment Unveiled
This story matters because it outlines a plausible way to extend the benefits of exclusive enteral nutrition (EEN) for Crohn's disease by using fecal microbiome transfer (FMT) to 'lock in' a healthier microbiome and...